Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BP sees Q2 hit from weak oil, gas prices; Production up

(Sharecast News) - BP on Friday said second-quarter earnings would be hit by weaker oil and gas prices, despite a rise in reported upstream production compared to the previous three months. Gas & low carbon energy segment, realisations, compared to the prior quarter, are expected to have an impact in the range of $100 - 300m, the company said in a quarterly trading update.

In the oil production & operations segment, quarter on quarter realisations are expected to have an impact in the range of $600 - 800m, including the production mix effects and the price lags on BP's production in the Gulf of Mexico and the UAE.

BP said crude oil prices averaged $67.88 a barrel in the second quarter, compared with $75.73 a barrel in the prior three months.

The energy giant's gas trading result is forecast to be average, although no details were provided. Average refining margins in the quarter are expected to rise to $21.1 a barrel from $15.2 a barrel.

Meanwhile the customers and products business was tipped set to benefit from those higher margins by $300m - $500m compared to the previous quarter, despite higher maintenance activity.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.